In an era where supply chain resilience and access to life-saving therapies dominate healthcare discussions, AstraZeneca's announcement of a $2 billion investment in Maryland facilities has captured significant attention, raising critical questions about domestic production. This ambitious
The pharmaceutical landscape is on the brink of a seismic shift with the introduction of the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, a bold initiative designed to cut the review timeline for drug and biological product applications from the standard 10-12 months down to
In the rapidly evolving field of biopharmaceuticals, a groundbreaking shift is capturing the attention of industry leaders and innovators alike, promising to redefine the development of advanced therapies with remarkable potential. This transformation centers on the adoption of cell-free DNA as a
The biopharmaceutical industry stands at a critical juncture where the integration of artificial intelligence (AI) into contract development and manufacturing organizations (CDMOs) is no longer a distant vision but a pressing reality. With the global biopharma market facing mounting pressure to
Imagine a world where damaged tissues and organs can be repaired using a resource readily available in the human body, transforming the landscape of medical treatment as we know it today. This vision is inching closer to reality with the remarkable advancements in fat stem cell research, a field
I'm thrilled to sit down with Ivan Kairatov, a seasoned biopharma expert with a wealth of experience in research and development. With a sharp focus on technology and innovation, Ivan has been at the forefront of advancing biologics formulation, particularly in tackling the complex challenges of
